

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Mabwell (Shanghai) Bioscience Co., Ltd.**

**邁威(上海)生物科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2493)**

## **POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING**

Reference is made to the circular of Mabwell (Shanghai) Bioscience Co., Ltd. (the “**Company**”) dated May 7, 2026 (the “**Circular**”) in relation to the 2026 second extraordinary general meeting (the “**EGM**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

### **CONVENING AND ATTENDANCE OF THE EGM**

The EGM was held at Conference Room 103, Building 3, Chuangxiang Park, No. 576, Libing Road, Pudong New Area, Shanghai, China, on Monday, June 1, 2026. The EGM was convened by the Board and presided over by Dr. Liu Datao, Chairman and the Executive Director. All Directors attended the EGM either in person or by electronic means.

The EGM was legally and validly convened in compliance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association of the Company.

As at the date of the EGM, (i) the total number of the issued Shares of the Company was 446,730,200 Shares, comprising 399,600,000 A Shares and 47,130,200 H Shares; (ii) the total number of treasury shares held by the Company was 1,192,369 A Shares and no voting right of treasury shares has been exercised at the EGM; (iii) there was no repurchased share which was pending cancellation and should therefore be excluded from the total number of issued shares entitling holders to attend and vote on all the resolutions at the EGM. The total number of Shares entitling the Shareholders to attend and vote on the resolution was 445,537,831 Shares. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the proposed resolution at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules and no Shareholder that was required under the Hong Kong Listing Rules to abstain from voting at the EGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM.

Voting for the resolution proposed to the Shareholders at the EGM was conducted by poll, which included both onsite voting by poll and, for A Shareholders only, online voting by poll. Tricor Investor Services Limited, the Company's H Share registrar, served as the scrutineers in respect of the vote-taking of H Shares at the EGM.

## POLL RESULTS OF THE EGM

The poll results are set out below.

Ordinary Resolution <sup>(1)</sup>		Number of Votes & Percentage of Voting Shares			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the application for the registration and issuance of targeted debt financing instruments	200,939,488 (99.7470%)	509,762 (0.2530%)	0 (0%)	Yes

Notes:

- (1) For details of the resolution, please refer to the Circular.
- (2) An ordinary resolution is passed by more than half of the votes casted in favor of it.

### WITNESS BY PRC LEGAL ADVISERS

The EGM was witnessed by Merits & Tree Law Offices, the PRC legal advisers of the Company, who issued a legal opinion, pursuant to which they are of the view that the convening of and the procedures for holding the EGM, the eligibility of the convener, and attendees and the voting procedures were in compliance with the requirements of the relevant laws and regulations and the provisions of the Articles of Association of the Company and that the poll results were valid.

By Order of the Board  
**Mabwell (Shanghai) Bioscience Co., Ltd.**  
**Dr. Liu Datao**  
*Chairman of the Board and Executive Director*

Shanghai, the PRC, June 1, 2026

*As at the date of this announcement, the directors of the Company are: (i) Mr. Tang Chunshan, Dr. Liu Datao (Chairman of the Board), Dr. Wu Hai, Mr. Hu Huiguo, Dr. Gui Xun as executive directors; (ii) Mr. Wu Yufeng as non-executive director; and (iii) Mr Qin Zhengyu, Dr. Xu Qing, Dr. Zhao Qian and Ms. Wang Fang as independent non-executive directors.*